Skip to content
The Policy VaultThe Policy Vault

Dupixent (dupilumab) — Highmark

Chronic Obstructive Pulmonary Disease (COPD)

Initial criteria

  • age ≥ 18 years
  • Diagnosis of COPD (ICD-10: J41-J44)
  • Post-bronchodilator FEV1 ≤ 80% predicted
  • Blood eosinophil count ≥300 cells/mcL OR currently taking daily or alternate-day oral corticosteroids
  • Modified Medical Research Council (mMRC) dyspnea scale score ≥2
  • Exacerbation history of at least two moderate exacerbations requiring systemic corticosteroids and/or antibiotics in the previous year